Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Keeping Track: Novartis' Ribociclib, Tesaro's Niraparib Submitted; Catalyst Clears Path For Firdapse Resubmission

Executive Summary

In retrospect, the European Society for Medical Oncology meeting was a showcase for pivotal trial data included in a burst of targeted therapy new drug applications, and more drug development news and highlights from our FDA Performance Tracker.


Related Content

Diabetes Treatment Shift Coming? Cleveland Clinic’s Nissen Declares Victory
Myriad's Ovarian Cancer Test Proves Its Mettle as Tesaro Companion Dx
Tesaro Takes Lead: Ovarian Cancer PhIII Pushes Niraparib Ahead Of Clovis' PARP Inhibitor
Novartis CDK4/6 Profile Boosted But Challenge To Pfizer Rival Uncertain
Keeping Track: Opdivo Dosing Simplified; Yosprala, Cuvitru Approved; Telotristat Review Lengthened
Keeping Track: Novartis, Calardius Pick Up Speed; ADMA Stumbles
Can A Safety Study Support A Superiority Claim? Barely, US FDA Advisors Say
Ariad Narrows Geographic Reach To Maximize Commercial Resources
Keeping Track: More Bumps On The Abuse-Deterrent Opioid Road
Novo Will Go After MACE Indication For Victoza Based On LEADER


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts